ORLANDO — Patients with severe asthma who are typically underrepresented in clinical studies experienced improved outcomes with tezepelumab in the real world, according to a poster presented at the American Thoracic Society Annual Meeting.Quality of life improved for these patients as well, Njira Lugogo, MD, clinical professor of medicine, division of pulmonary and critical care medicine,